Short Timeframe Prediction of Kidney Failure among Patients with Advanced Chronic Kidney Disease.

BACKGROUND: Development of a short timeframe (6-12 months) kidney failure risk prediction model may serve to improve transitions from advanced chronic kidney disease (CKD) to kidney failure and reduce rates of unplanned dialysis. The optimal model for short timeframe kidney failure risk prediction remains unknown. METHODS: This retrospective study included 1757 consecutive patients with advanced CKD (mean age 66 years, estimated glomerular filtration rate 18 mL/min/1.73 m2). We compared the performance of Cox regression models using (a) baseline variables alone, (b) time-varying variables and machine learning models, (c) random survival forest, (d) random forest classifier in the prediction of kidney failure over 6/12/24 months. Performance metrics included area under the receiver operating characteristic curve (AUC-ROC) and maximum precision at 70% recall (PrRe70). Top-performing models were applied to 2 independent external cohorts. RESULTS: Compared to the baseline Cox model, the machine learning and time-varying Cox models demonstrated higher 6-month performance [Cox baseline: AUC-ROC 0.85 (95% CI 0.84-0.86), PrRe70 0.53 (95% CI 0.51-0.55); Cox time-varying: AUC-ROC 0.88 (95% CI 0.87-0.89), PrRe70 0.62 (95% CI 0.60-0.64); random survival forest: AUC-ROC 0.87 (95% CI 0.86-0.88), PrRe70 0.61 (95% CI 0.57-0.64); random forest classifier AUC-ROC 0.88 (95% CI 0.87-0.89), PrRe70 0.62 (95% CI 0.59-0.65)]. These trends persisted, but were less pronounced, at 12 months. The random forest classifier was the highest performing model at 6 and 12 months. At 24 months, all models performed similarly. Model performance did not significantly degrade upon external validation. CONCLUSIONS: When predicting kidney failure over short timeframes among patients with advanced CKD, machine learning incorporating time-updated data provides enhanced performance compared with traditional Cox models.

Duration of Breastfeeding Interruption in Nuclear Medicine Procedures.

The recommendation for the duration of breastfeeding interruption after radiopharmaceutical administration has not been standardized and varies among the guidance documents and publications in the literature. Methods: A working group consisting of 3 staff physicians, 2 fellows, and 2 technologists was designated to update the institutional recommendations on breastfeeding interruption based on the review of the guidance documents and the literature. Results: Our institutional recommendations on the duration of breastfeeding interruption for 54 radiopharmaceuticals are presented in 4 summary tables. For completeness, we also include other radiopharmaceuticals with available information. Conclusion: The detailed recommendation summary on breastfeeding might be helpful to other centers.

The Past, Present, and Future Role of Artificial Intelligence in Ventilation/Perfusion Scintigraphy: A Systematic Review.

Ventilation-perfusion (V/Q) lung scans constitute one of the oldest nuclear medicine procedures, remain one of the few studies performed in the acute setting, and are amongst the few performed in the emergency setting. V/Q studies have witnessed a long fluctuation in adoption rates in parallel to continuous advances in image processing and computer vision techniques. This review provides an overview on the status of artificial intelligence (AI) in V/Q scintigraphy. To clearly assess the past, current, and future role of AI in V/Q scans, we conducted a systematic Ovid MEDLINE(R) literature search from 1946 to August 5, 2022 in addition to a manual search. The literature was reviewed and summarized in terms of methodologies and results for the various applications of AI to V/Q scans. The PRISMA guidelines were followed. Thirty-one publications fulfilled our search criteria and were grouped into two distinct categories: (1) disease diagnosis/detection (N = 22, 71.0%) and (2) cross-modality image translation into V/Q images (N = 9, 29.0%). Studies on disease diagnosis and detection relied heavily on shallow artificial neural networks for acute pulmonary embolism (PE) diagnosis and were primarily published between the mid-1990s and early 2000s. Recent applications almost exclusively regard image translation tasks from CT to ventilation or perfusion images with modern algorithms, such as convolutional neural networks, and were published between 2019 and 2022. AI research in V/Q scintigraphy for acute PE diagnosis in the mid-90s to early 2000s yielded promising results but has since been largely neglected and thus have yet to benefit from today's state-of-the art machine-learning techniques, such as deep neural networks. Recently, the main application of AI for V/Q has shifted towards generating synthetic ventilation and perfusion images from CT. There is therefore considerable potential to expand and modernize the use of real V/Q studies with state-of-the-art deep learning approaches, especially for workflow optimization and PE detection at both acute and chronic stages. We discuss future challenges and potential directions to compensate for the lag in this domain and enhance the value of this traditional nuclear medicine scan.

COMP Report: CPQR technical quality control guidelines for use of positron emission tomography/computed tomography in radiation treatment planning.

Positron emission tomography with x-ray computed tomography (PET/CT) is increasingly being utilized for radiation treatment planning (RTP). Accurate delivery of RT therefore depends on quality PET/CT data. This study covers quality control (QC) procedures required for PET/CT for diagnostic imaging and incremental QC required for RTP. Based on a review of the literature, it compiles a list of recommended tests, performance frequencies, and tolerances, as well as references to documents detailing how to perform each test. The report was commissioned by the Canadian Organization of Medical Physicists as part of the Canadian Partnership for Quality Radiotherapy initiative.

Intensity of hypermetabolic axillary lymph nodes in oncologic patients in relation to timeline following COVID-19 vaccination.

PURPOSE: First discovered in Wuhan, China in December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) is a highly contagious and deadly novel virus that quickly wreaked havoc throughout the world. As mass vaccination are now underway worldwide, clinicians have started to encounter a new clinical entity, COVID-19 vaccine-associated axillary lymphadenopathy. This presents a unique challenge to medical imagers, particularly in oncologic patients. METHODS: In this retrospective study, we assessed metabolic activity, size, and timeline of COVID-19 vaccine-associated axillary hypermetabolic lymph nodes in 202 oncologic patients post vaccination with 18-fluorodeoxyglucose positron emission tomography (18-FDG PET). RESULTS: When present, COVID-19 vaccine-associated hypermetabolic lymph nodes demonstrate a mean maximum standard uptake value (SUVmax) of 2.5 ± 0.3, and more common in younger patients. The metabolic activity is the most intense in the first two weeks post vaccination and diminishes over time. By approximately 5-6 weeks, only about half of the patients demonstrated appreciable, low grade uptake compared to background. CONCLUSION: Based on our preliminary results, we would recommend correlation with a history and time of vaccination and routine use of a pre-study patient questionnaire to guide interpretation to prevent over-diagnosis of axillary nodal metastases and/or unnecessary work-up in oncologic patients.

Thyroid Uptake Exceeding 100%: Causes and Prevention.

Background: Radionuclide thyroid uptake measurements reflect the metabolic activity of the thyroid gland. Thyroid uptake is measured as a percentage of radioactivity retained by the gland at a specified time versus the activity administered to the patient; thus, uptake measurements must fall between 0 and 100%. In this study we review sources of errors that can lead to uptake >100% through a case study and describe a novel quality control (QC) indicator to improve the accuracy of uptake measurements in the clinic. Methods: Probe efficiency is determined as the ratio between dose counts of the probe relative to the independent dose calibrator activity readings. The nominal probe efficiency value (M) was calculated as the mean of readings (n≥20) and variance was characterized using the standard-deviation (SD). Warning levels were set at M±1.96×SD and error levels were set to M±2.58×SD. In subsequent routine clinical use, prior to administrating a capsule, the probe efficiency is calculated and compared with the warning and error limits. We derived M for three pairs of probe and dose-calibrator devices using several doses and measured independently by several nuclear medicine technologists. Results: The recorded data indicated that nominal efficiency was statistically different between our old device and the one that replaced it (P = 0.01) but coefficient-of-variation(CV% =SD/M×100%) was not (P = 0.42) when technologists were made aware of the expected efficiency value. Using efficiency measurements of the first 20 first patients acquired on the replacement device new QC values were derived (M= 910, SD =36). In 22 patients measured at our sister site, with the same device models but without technologists being aware of QC initiative, derived QC values were (M =1025, SD =116), demonstrating a significant difference between nominal values of individual devices (p<0.001). Furthermore, variability was significantly lower (p<0.001) when QC was followed compared to when it was not applied. Conclusion: Adding the probe efficiency as a quality control indicator during thyroid uptake measurement is simple, can produce more precise clinical measurement and help mitigate operator and instrumentation errors.

Increased myocardial oxygen consumption rates are associated with maladaptive right ventricular remodeling and decreased event-free survival in heart failure patients.

BACKGROUND: Reduced left ventricular (LV) function is associated with increased myocardial oxygen consumption rate (MVO2) and altered sympathetic activity, the role of which is not well described in right ventricular (RV) dysfunction. METHODS AND RESULTS: 33 patients with left heart failure were assessed for RV function/size using echocardiography. Positron emission tomography (PET) was used to measure 11C-acetate clearance rate (kmono), 11C-hydroxyephedrine (11C-HED) standardized uptake value (SUV), and retention rate. RV MVO2 was estimated from kmono. 11C-HED SUV and retention indicated sympathetic neuronal function. A composite clinical endpoint was defined as unplanned cardiac hospitalization within 5 years. Patients with (n = 10) or without (n = 23) RV dysfunction were comparable in terms of sex (male: 70.0 vs 69.5%), LV ejection fraction (39.6 ± 9.0 vs 38.6 ± 9.4%), and systemic hypertension (70.0 vs 78.3%). RV dysfunction patients were older (70.9 ± 13.5 vs 59.4 ± 11.5 years; P = .03) and had a higher prevalence of pulmonary hypertension (60.0% vs 13.0%; P = .01). RV dysfunction was associated with increased RV MVO2 (.106 ± .042 vs .068 ± .031 mL/min/g; P = .02) and decreased 11C-HED SUV and retention (6.05 ± .53 vs 7.40 ± 1.39 g/mL (P < .001) and .08 ± .02 vs .11 ± .03 mL/min/g (P < .001), respectively). Patients with an RV MVO2 above the median had a shorter event-free survival (hazard ratio = 5.47; P = .01). Patients who died within the 5-year follow-up period showed a trend (not statistically significant) for higher RV MVO2 (.120 ± .026 vs .074 ± .038 mL/min/g; P = .05). CONCLUSIONS: RV dysfunction is associated with increased oxygen consumption (also characterized by a higher risk for cardiac events) and impaired RV sympathetic function.

Guidelines on Setting Up Stations for Remote Viewing of Nuclear Medicine and Molecular Imaging Studies During COVID-19.

The current pandemic has created a situation where nuclear medicine practitioners and medical physicists read or process nuclear medicine images remotely from their home office. This article presents recommendations on the components and specifications when setting up a remote viewing station for nuclear medicine imaging.

Selection of PET Camera and Implications on the Reliability and Accuracy of Absolute Myocardial Blood Flow Quantification.

PURPOSE OF REVIEW: PET scanner design and performance evaluation has been driven historically by the imaging requirements for whole-body imaging in oncology. Cardiac PET imaging for accurate quantification of myocardial blood flow (MBF) using short-lived tracers such as rubidium-82 imposes additional requirements for wide dynamic range and high count-rate accuracy. This paper examines the technical challenges encountered in cardiac imaging of myocardial perfusion and blood flow quantification. RECENT FINDINGS: The newest PET-CT scanners using digital silicon photomultiplier technology have high absolute sensitivity (4-20%) and time-of-flight resolution (3-7 cm) which further improves image quality. The concept of "integral" noise equivalent counts (iNEC) is introduced to compare scanner count-rate performance over the wide dynamic range encountered in MBF imaging with rubidium-82. The latest-generation digital PET scanners with wide axial field-of-view and enhanced time-of-flight resolution should enable accurate quantification of MBF, without any compromise in the quality of conventional ECG-gated myocardial perfusion images.

Rubidium-82 generator yield and efficiency for PET perfusion imaging: Comparison of two clinical systems.

INTRODUCTION: Strontium-82/Rubidium-82 (82Sr/82Rb) generators are used widely for positron emission tomography (PET) imaging of myocardial perfusion. In this study, the 82Rb isotope yield and production efficiency of two FDA-approved 82Sr/82Rb generators were compared. METHODS: N = 515 sequential daily quality assurance (QA) reports from 9 CardioGen-82® and 9 RUBY-FILL® generators were reviewed over a period of 2 years. A series of test elutions was performed at different flow-rates on the RUBY-FILL® system to determine an empirical correction-factor used to convert CardioGen-82® daily QA values of 82Rb activity (dose-calibrator 'maximum' of 50 mL elution at 50 mL·min-1) to RUBY-FILL® equivalent values (integrated 'total' of 35 mL elution at 20 mL·min-1). The generator yield (82Rb) and production efficiency (82Rb yield/82Sr parent activity) were measured and compared after this conversion to a common scale. RESULTS: At the start of clinical use, the system reported 82Rb activity from daily QA was lower for CardioGen-82® vs RUBY-FILL® (2.3 ± 0.2 vs 3.0 ± 0.2 GBq, P < 0.001) despite having similar 82Sr activity. Dose-calibrator 'maximum' (CardioGen-82®) values were found to under-estimate the integrated 'total' (RUBY-FILL®) activity by ~ 24% at 50 mL·min-1. When these data were used to convert the CardioGen-82 values to a common measurement scale (integrated total activity) the CardioGen-82® efficiency remained slightly lower than the RUBY-FILL® system on average (88 ± 4% vs 95 ± 4%, P < 0.001). The efficiency of 82Rb production improved for both systems over the respective periods of clinical use. CONCLUSIONS: 82Rb generator yield was significantly under-estimated using the CardioGen-82® vs RUBY-FILL® daily QA procedure. When generator yield was expressed as the integrated total activity for both systems, the estimated 82Rb production efficiency of the CardioGen-82® system was ~ 7% lower than RUBY-FILL® over the full period of clinical use.

Validation of regional myocardial blood flow quantification using three-dimensional PET with rubidium-82: repeatability and comparison with two-dimensional PET data acquisition.

INTRODUCTION: Three-dimensional (3D) data acquisition is now standard on PET/computed tomography scanners. The aim of this study was to evaluate the repeatability of myocardial blood flow (MBF) estimation with rubidium-82 (Rb) 3D PET and to validate regional MBF measurements by comparison with two-dimensional (2D) PET. PATIENTS AND METHODS: Fifteen healthy individuals (31.6 ± 11.4 years old) were enrolled for the evaluation of the short-term repeatability of rest 3D MBF quantification. Another 19 healthy individuals (35.3 ± 12.6 years old) underwent rest and pharmacological stress PET using 2D and 3D data acquisition within a 1-month interval. The injected dose was 1500 MBq for 2D and 555 MBq for 3D PET acquisition. RESULTS: MBF at rest showed good repeatability [whole left ventricular MBF; 0.54 ± 0.13 vs. 0.52 ± 0.13 mL/min/g, P = 0.98]. Rest MBF, stress MBF, and myocardial flow reserve (MFR) were not significantly different between 3D and 2D data acquisition. 3D MBF correlated well with 2D MBF over a wide flow range for both whole left ventricular (r = 0.97, P < 0.0001) and regional values (r = 0.61, P < 0.0001). CONCLUSION: MBF measured with 3D PET showed very good test-retest repeatability. Whole left ventricular and regional MBF measurements obtained using lower Rb-dose 3D PET were highly correlated over a wide range with those from 2D PET. Therefore, MBF with 3D PET can be applied using a lower Rb dosage in clinical settings with reduced radiation exposure.

PET and SPECT Tracers for Myocardial Perfusion Imaging.

Coronary artery disease has been the leading cause of death since the 1960s, which has motivated the research and development of myocardial perfusion imaging (MPI) agents for early diagnosis and to guide treatment. MPI with SPECT has been the clinical workhorse for MPI, but over the past two decades PET MPI is experiencing growth due to enhanced image quality that results in superior diagnostic accuracy over SPECT. Furthermore, dynamic PET imaging of the tracer distribution process from time of tracer administration to tracer accumulation in the myocardium has enabled routine quantification of myocardial blood flow (MBF) and myocardial flow reserve (MFR) in absolute units. MBF and MFR incrementally improve diagnostic and prognostic accuracy over MPI alone. In some cases (eg, rubidium PET imaging with pharmacologic stress) MPI, MBF, and MFR can be acquired simultaneously without incremental cost, radiation exposure, or significant processing time. Nuclear cardiology clinics have been looking to incorporate MBF quantification into clinical routine, but traditional SPECT and MPI tracers are inadequate for this challenge. Cardiac dedicated SPECT scanners can also perform dynamic imaging and have stimulated research into MBF quantification using SPECT tracers. New perfusion tracers must be tailored for emerging clinical needs (including MBF quantification), technical capabilities of imaging instrumentation, market constraints, and supply chain feasibility. Because these conditions have been evolving, tracers previously considered inferior may be reconsidered for future applications and some recently developed tracers may be suboptimal. This article reviews current, clinically-available tracers and those under development showing greatest potential. It discusses for each tracer the rationale for development, physiological mechanism of uptake by the myocardium, published evaluation results and development state. Finally, it gauges the suitability of each tracer for clinical application. The article demonstrates an acceleration in the pace of perfusion radiotracer development due to better understanding of the relevant physiology, better chemistry tools and small animal imaging. Consequently, bad tracers may fail faster and with less wasted investment, and good tracers may translate more efficiently from bench to bedside.

Development and validation of the Lesion Synthesis Toolbox and the Perception Study Tool for quantifying observer limits of detection of lesions in positron emission tomography.

Purpose: Accurate detection of cancer lesions in positron emission tomography (PET) is fundamental to achieving favorable clinical outcomes. Therefore, image reconstruction, processing, visualization, and interpretation techniques must be optimized for this task. The objective of this work was to (1) develop and validate an efficient method to generate well-characterized synthetic lesions in real patient data and (2) to apply these lesions in a human perception experiment to establish baseline measurements of the limits of lesion detection as a function of lesion size and contrast using current imaging technologies. Approach: A fully integrated software package for synthesizing well-characterized lesions in real patient PET was developed using a vendor provided PET image reconstruction toolbox (REGRECON5, General Electric Healthcare, Waukesha, Wisconsin). Lesion characteristics were validated experimentally for geometric accuracy, activity accuracy, and absence of artifacts. The Lesion Synthesis Toolbox was used to generate a library of 133 synthetic lesions of varying sizes ( n = 7 ) and contrast levels ( n = 19 ) in manually defined locations in the livers of 37 patient studies. A lesion-localization perception study was performed with seven observers to determine the limits of detection with regard to lesion size and contrast using our web-based perception study tool. Results: The Lesion Synthesis Toolbox was validated for accurate lesion placement and size. Lesion intensities were deemed accurate with slightly elevated activities (5% at 2:1 lesion-to-background contrast) in small lesions ( Ø = 15 mm spheres), and no bias in large lesions ( Ø = 22.5 mm ). Bed-stitching artifacts were not observed, and lesion attenuation correction bias was small ( - 1.6 ± 1.2 % ). The 133 liver lesions were synthesized in ∼ 50 h , and readers were able to complete the perception study of these lesions in 12 ± 3 min with consistent limits of detection amongst all readers. Conclusions: Our open-source utilities can be employed by nonexperts to generate well-characterized synthetic lesions in real patient PET images and for administering perception studies on clinical workstations without the need to install proprietary software.

Clinical comparison of the positron emission tracking (PeTrack) algorithm with the real-time position management system for respiratory gating in cardiac positron emission tomography.

PURPOSE: A data-driven motion tracking system was developed for respiratory gating in positron emission tomography (PET)/computed tomography (CT) studies. The positron emission tracking system (PeTrack) estimates the position of a low-activity fiducial marker placed on the patient during imaging. The aim of this study was to compare the performance of PeTrack against that of the real-time position management (RPM) system as applied to respiratory gating in cardiac PET/CT studies. METHODS: The list-mode data of 35 patients that were referred for 82 Rb myocardial perfusion studies were retrospectively processed with PeTrack to generate respiratory motion signals and triggers. Fifty acquisitions from the initial cohort, conducted under physiologic rest and stress, were considered for analysis. Respiratory-gated reconstructions were performed using reconstruction software provided by the vendor. The respiratory signals and triggers of the gating systems were compared using quantitative measurements of the respiratory signal correlation, median, and interquartiles range (IQR) of observed respiratory rates and the relative frequencies of respiratory cycle outliers. Quantitative measurements of left-ventricular wall thicknesses and motion due to respiration were also compared. Real-time position management signals were also retrospectively processed using the trigger detection method of PeTrack for a third comparator ("RPMretro") that allowed direct comparison of the motion tracking quality independently of differences in the trigger detection methods. The comparison of PeTrack to the original RPM data represent a practical comparison of the two systems, whereas that of PeTrack and RPMretro represents an equal comparison of the two. Nongated images were also reconstructed to provide reference left-ventricular wall thicknesses. LV wall thickness and motion measurements were repeated for a subset of cases with motion ≥7 mm as image artifacts were expected to be more severe in these cases. RESULTS: A significant correlation (P < 0.05) was observed between the RPM and PeTrack respiratory signals in 45/50 acquisitions; the mean correlation coefficient was 0.43. Similar results were found between PeTrack and RPMretro. No significant difference was observed between the RPM and PeTrack with respect to median respiratory rates and the percentage of respiratory cycles outliers. Respiratory rate variability (IQR) was significantly higher with PeTrack vs RPM (P = 0.002) and RPMretro (P = 0.04). Both PeTrack and RPM had a significant increase in the percentage of respiratory rate outliers compared to RPMretro (P < 0.001 and P = 0.001, respectively). All methods indicated significant differences in LV thickness compared to nongated images (P < 0.02). LV thickness was significantly larger for PeTrack compared to RPMretro in the highest motion subset (P = 0.009). Images gated with RPMretro showed significant increases in motion compared to both PeTrack (P < 0.001) and prospective RPM (P = 0.002). In the subset of highest motion cases, the difference between RPM and RPMretro was no longer present. CONCLUSIONS: The data-driven PeTrack algorithm performed similarly to the well-established RPM system for respiratory gating of 82 Rb cardiac perfusion PET/CT studies. Real-time position management performance improved after retrospective processing and led to enhanced performance compared to both PeTrack and prospective RPM. With further development PeTrack has the potential to reduce the need for ancillary hardware systems to monitor respiratory motion.

Quantitative blood flow evaluation of vasodilation-stress compared with dobutamine-stress in patients with end-stage liver disease using 82Rb PET/CT.

BACKGROUND: Our aim was to determine if end-stage liver disease (ESLD) is associated with an attenuated response to vasodilator-stress or dobutamine-stress using 82Rb-PET MPI with blood flow quantification. METHODS AND RESULTS: Pre-liver transplant patients who had a normal dipyridamole-stress (n = 27) or dobutamine-stress (n = 26) 82Rb PET/CT MPI study with no identifiable coronary artery calcium were identified retrospectively and compared to a prospectively identified low-risk of liver disease dipyridamole-stress control group (n = 20). The dipyridamole-stress liver disease group had a lower myocardial flow reserve (MFR) (1.89 ± 0.79) than the control group (2.79 ± 0.96, P < .05). The dobutamine-stress group had a higher MFR than both other groups (3.69 ± 1.49, P < .05). A moderate negative correlation between MELD score and MFR was demonstrated for the dipyridamole-stress liver disease group (r = - 0.473, P < .05). This correlation was not observed for the dobutamine-stress liver disease group (r = - 0.253, P = .21). The liver failure group as a whole (n = 53) had a higher resting myocardial blood flow (0.97 ± 0.33 mL/min/g) than the control group (0.82 ± 0.26, P < .05). CONCLUSION: Dipyridamole demonstrates an attenuated vasodilatory response in ESLD patients compared to a non-ESLD control group related to higher resting blood flow and comparatively reduced stress blood flow. Dobutamine does not demonstrate this effect implying it may be the preferred pharmacologic MPI stress agent for ESLD patients.

Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling.

BACKGROUND: The induction of matrix metalloproteinases (MMPs) and reduction in tissue inhibitors of MMPs (TIMPs) plays a role in ischemia/reperfusion (I/R) injury post-myocardial infarction (MI) and subsequent left ventricular remodeling. We developed a hybrid dual isotope single-photon emission computed tomography/computed tomography approach for noninvasive evaluation of regional myocardial MMP activation with 99mTc-RP805 and dynamic 201Tl for determination of myocardial blood flow, to quantify the effects of intracoronary delivery of recombinant TIMP-3 (rTIMP-3) on I/R injury. METHODS: Studies were performed in control pigs (n=5) and pigs following 90-minute balloon occlusion-induced ischemia/reperfusion (I/R) of left anterior descending artery (n=9). Before reperfusion, pigs with I/R were randomly assigned to intracoronary infusion of rTIMP-3 (1.0 mg/kg; n=5) or saline (n=4). Three days post-I/R, dual isotope imaging was performed with 99mTc-RP805 and 201Tl along with contrast cineCT to assess left ventricular function. RESULTS: The ischemic to nonischemic ratio of 99mTc-RP805 was significantly increased following I/R in saline group (4.03±1.40), and this ratio was significantly reduced with rTIMP-3 treatment (2.22±0.57; P=0.03). This reduction in MMP activity in the MI-rTIMP-3 treatment group was associated with an improvement in relative MI region myocardial blood flow compared with the MI-saline group and improved myocardial strain in the MI region. CONCLUSIONS: We have established a novel hybrid single-photon emission computed tomography/computed tomography imaging approach for the quantitative assessment of regional MMP activation, myocardial blood flow, and cardiac function post-I/R that can be used to evaluate therapeutic interventions such as intracoronary delivery of rTIMP-3 for reduction of I/R injury in the early phases of post-MI remodeling.

Machine Learning and Deep Learning in Medical Imaging: Intelligent Imaging.

Artificial intelligence (AI) in medical imaging is a potentially disruptive technology. An understanding of the principles and application of radiomics, artificial neural networks, machine learning, and deep learning is an essential foundation to weave design solutions that accommodate ethical and regulatory requirements, and to craft AI-based algorithms that enhance outcomes, quality, and efficiency. Moreover, a more holistic perspective of applications, opportunities, and challenges from a programmatic perspective contributes to ethical and sustainable implementation of AI solutions.

Accurate GFR in obesity-protocol for a systematic review.

BACKGROUND: Obesity is increasing globally. Chronic kidney disease (CKD) is strongly associated with obesity. Kidney function is commonly estimated with equations using creatinine (such as CKD-EPI equation) which is a product of muscle metabolism. Decisions about categorizing CKD, planning modality of renal replacement therapies, and adjusting dosages of medications excreted by the kidneys are done using these equations. However, it is not well appreciated that creatinine-based equations may not accurately estimate kidney function in obese individuals. We plan a systematic review of diagnostic studies which will compare estimating equations to actual measured kidney function. METHODS: We will systematically search electronic bibliographic databases including MEDLINE, EMBASE, and the Cochrane Library with no restrictions on language or specific dates. The search terms will be adapted for the different databases using a combination of Medical Subject Heading and relevant keywords contained in titles and abstracts. Our preliminary search strategy using Cochrane, MEDLINE, and EMBASE databases have identified 190, 1246, and 1660 citations, respectively. For all studies selected, we will extract information on general study characteristics, study participant (age, sex, ethnicity, weight, height, BMI, BSA), type and protocol of reference standard utilized, the index test studied, the methodology of measurement of index test, categories of GFR, the proportion of eGFR within 10, 20, 30, 40, and 50% of measured GFR, and bias between eGFR and measured GFR. If the quality of methods and risk of bias are adequate, we will perform a meta-analysis. We will assess the heterogeneity using the χ 2 and the I 2 statistics to examine whether the estimates from studies included could be pooled. Sensitivity and multivariate meta-regression analyses will be performed to assess the effects of clinical factors and socio-demographic characteristics reported in included studies on the meta-analytic estimates. All analysis will be performed using the Comprehensive Meta-analysis software. DISCUSSION: This systematic review might help to inform clinicians on the best equation to use in patients with obesity and CKD for staging of CKD and for medication dosing. If no equation is deemed suitable, this review will form a basis for future studies of GFR in obese individuals. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42018104345.